StereoCav : Randomised trial of adjuvant versus delayed stereotactic radiotherapy to resection cavity of brain metastases and quality of life outcomes

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Radiotherapy<br/>TrialTypeRadiotherapy
Trial

TwoPhase Two

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Radiotherapy | Blood / Myeloma / Lymphoma,Bowel (colorectum),Brain and spinal cord,Breast,Female reproductive organs,Head and neck,Lung,Sarcoma,Skin,Stomach and upper gastrointestinal tract,Urinary systemAcute Lymphoblastic Leukaemia,Acute Myeloid Leukaemia,Acute Promyelocytic Leukaemia,Adrenocortical carcinoma,Amyloidosis,Anus,Aplastic Anaemia,Astrocytoma,Basal cell carcinoma,Bile duct,Bladder,Bone,Brain,Brain stem,Breast,Central Nervous System,Cervix,Chondrosarcoma,Melanoma (Ocular),Chronic Lymphocytic Leukaemia,Chronic Myelogenous Leukaemia,Colon,Colorectum,Melanoma (Skin),Cutaneous Squamous Cell Carcinoma (CSCC),Endometrium,Ependymomas,Epithelial,Essential Thrombocytosis,Ewing's Sarcoma,Fallopian tube,Gallbladder,Gastrointestinal stromal tumour (GIST),Gastro-oesophageal junction ,Glioblastoma (GBM) ,Glioma,Head and neck,Kidney,Langerhans Cell Histiocytosis,Leiomyosarcoma,Leukaemia,Liposarcoma,Liver,Lung,Medullablastoma,Melanoma (Skin),Meningioma,Merkel cell,Mesothelioma,Mouth (including tonsil, tongue, soft palate, cheeks, lips, gum),Multiple Myeloma,Neuroblastoma,Non-Small Cell Lung Cancer,Nose (nasopharynx),Oesophagus,Oral cavity,Oropharynx,Osteosarcoma,Ovary,Pancreas,Penis,Peritoneal,Prostate,Rectum,Renal cell carcinoma,Rhabdomyosarcoma,Salivary glands,Sarcoma,Small Cell Lung Cancer,Soft Tissue Sarcoma,Spinal Cord,Squamous cell carcinoma ,Stomach,Synovial Sarcoma,Testis,Throat (hypopharynx),Thyroid,Urinary tract,Urothelial,Uterus,Melanoma (Ocular),Vagina,Voice box (larynx),Vulva

Trial Overview Read MoreRead more

This phase II trial is comparing adjuvant radiotherapy with delayed radiotherapy in people who have previously resected cancer that has spread to the brain.
 

This trial is treating patients with brain metastases.

This is a radiotherapy trial.

You may be able to join this trial if:

  • You have had a certain type of treatment or surgical procedure.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Randomised trial of adjuvant versus delayed stereotactic radiotherapy to resection cavity of brain metastases and quality of life outcomes

Other Non-Commercial Sponsor

William Buckland Radiotherapy Centre

Summary

The study aims to address whether the timing of stereotactic radiotherapy (SRT) after surgical removal of brain metastases impacts on quality of life; that is, whether treatment on local recurrence (disease returning at the surgical cavity) impacts on quality of life more than upfront SRT following resection of brain metastases. Who is it for? You may be eligible to participate in this study if you are aged 18 years or above and have had 1-3 brain metastases surgically removed. Study details: After surgical removal of brain metastases, in the absence of further treatment, about half of patients will develop a recurrence (disease returning) within the surgical cavity(s), while about half will not. For patients who had 1-3 brain metastases surgically removed, SRT targeting the surgical cavity(s) has been shown to provide local control rates of 70-90% at 1 year. Nevertheless, approximately 50% of patients are destined to never recur at the surgical cavity(s); hence close observation, with radiotherapy at the first sign of recurrence is also often practised. This approach spares treatment in potentially half of patients. By using regular 3-monthly MRIs of the brain, most recurrences should be detected while they are small and before symptoms develop. The study aims to address whether the timing of SRT after surgical removal of brain metastases impacts on quality of life. We are also studying the effect of treatment on patient’s neurocognitive function (memory, thinking processes). It is hypothesized that delivering SRT on local recurrence is no worse than upfront SRT to resection cavity in terms of patient’s quality of life.

Recruiting Hospitals Read MoreRead more

Alfred Hospital, William Buckland Radiotherapy Centre
Prahran
Ms Robin Smith
robin.smith@wbrc.org.au
03 9076 2360

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next